Buy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial Progress

TipRanksSep 4 06:27 ET · Ratings

Express News | Longeveron Inc - Alignment With FDA on Elpis II Primary and Secondary Endpoints

ReutersSep 3 09:00 ET

Express News | Longeveron Inc - Company to Submit Sap and Cmc Readiness Plan to FDA

ReutersSep 3 09:00 ET

Express News | Longeveron® Announces Positive Type C Meeting With U.S. FDA Regarding Pathway to Bla for Lomecel-B™ in Hypoplastic Left Heart Syndrome (Hlhs)

ReutersSep 3 09:00 ET

Beyond The Numbers: 4 Analysts Discuss Longeveron Stock

BenzingaAug 27 11:00 ET

Maxim Group Maintains Longeveron(LGVN.US) With Buy Rating, Cuts Target Price to $6

Moomoo NewsAug 27 09:31 ET · Ratings